On March 4, 2025 GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE natural killer (NK) cell engager platform, reported that Jeffrey Miller, MD1 from the University of Minnesota Medical School will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San Diego, CA (Press release, GT Biopharma, MAR 4, 2025, View Source [SID1234650880]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
10th Anniversary of the Innate Killer Summit
Title: Showcasing Advantages of Tri-Specific Killer Engagers to Turbocharge NK Recruitment & Potency
Date: Tuesday, March 4, 2025
Time: 1:30 pm PT
Participant: Dr. Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, Co-Leader Immunology Program at the University of Minnesota Medical School & Consulting Senior Medical Director, GT Biopharma
Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and increase cytokine release, and the preclinical and clinical data shown to date.
GTB-3650, GT Biopharma’s wholly owned second-generation TriKE, is currently being evaluated in a Phase 1 dose escalation study in patients with hematological malignancies. Enrollment is proceeding as expected, marking consistent advancement in the trial which will evaluate GTB-3650 in up to approximately 14 patients (seven cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The company anticipates sharing initial data from the study in 2025. More details can be found on clinicaltrials.gov with the identifier: NCT06594445.